{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:32:11Z","timestamp":1793143931302,"version":"4.5.0"},"reference-count":0,"publisher":"Kare Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol Forum"],"abstract":"<jats:p>Background and Aim: Hepatotoxicity represents a significant adverse effect associated with cancer treatment. The present study was designed to evaluate the possible hepatoprotective effects of bevacizumab and nivolumab when administered concomitantly with cisplatin.\r\nMaterials and Methods: A total of forty-two male Wistar Albino rats were randomly allocated into six groups: control, bevacizumab (10 mg\/kg), nivolumab (3 mg\/kg), cisplatin (12 mg\/kg), cisplatin plus bevacizumab, and cisplatin plus nivolumab. Histological assessment of liver tissues was performed using hematoxylin and eosin (H&amp;E) and Masson\u2019s trichrome staining. Immunohistochemical evaluation was conducted for inflammatory markers (TNF-\u03b1, IL-6), the angiogenic factor VEGF, and apoptotic markers (Bax, Bcl-2, Caspase-3).\r\nResults: Administration of cisplatin resulted in hepatotoxic changes, including disruption of normal hepatic cord architecture, cytoplasmic vacuolization, hemorrhage, mononuclear cell infiltration, and enhanced collagen accumulation. Co-treatment with bevacizumab or nivolumab significantly alleviated these histopathological changes (p<\/jats:p>","DOI":"10.14744\/hf.2025.01128","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:48:43Z","timestamp":1768481323000},"page":"45-50","source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab and bevacizumab attenuate cisplatin-induced hepatic inflammation and apoptosis in rats"],"prefix":"10.14744","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7140-8957","authenticated-orcid":false,"given":"Ogur","family":"Karhan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Harran University, Sanliurfa, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0946-0700","authenticated-orcid":false,"given":"Sibel","family":"Turedi","sequence":"additional","affiliation":[{"name":"Department of Histology and Embryology, School of Medicine, Harran University, Sanliurfa, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5966","published-online":{"date-parts":[[2026]]},"container-title":["Hepatology Forum"],"original-title":[],"link":[{"URL":"https:\/\/file.paplino.com\/hepatologyforum\/pdfs\/1768478537-en.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/hepatologyforum.org\/storage\/upload\/pdfs\/1768478537-en.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:45:10Z","timestamp":1793141110000},"score":1,"resource":{"primary":{"URL":"https:\/\/hepatologyforum.org\/articles\/HF-01128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.14744\/hf.2025.01128","relation":{},"ISSN":["1307-5888","2757-7392"],"issn-type":[{"value":"1307-5888","type":"print"},{"value":"2757-7392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}